+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Non-insulin Diabetes Therapeutics Market 2021-2025- Product Image
Global Non-insulin Diabetes Therapeutics Market 2021-2025- Product Image

Global Non-insulin Diabetes Therapeutics Market 2021-2025

  • ID: 5351697
  • Report
  • May 2021
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the non-insulin diabetes therapeutics market and it is poised to grow by $22.95 billion during 2021-2025, progressing at a CAGR of over 10% during the forecast period. The report on non-insulin diabetes therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing number of people with type 2 diabetes and the growing prevalence of diabetes among people aged 6-19 and 35-50. In addition, the increasing number of people with type 2 diabetes is anticipated to boost the growth of the market as well.

The non-insulin diabetes therapeutics market analysis includes the type segment and geographic landscape.

The non-insulin diabetes therapeutics market is segmented as below:

By Type
  • DPP4 inhibitor
  • GLP-1 receptor agonist
  • SGLT2 inhibitor
  • Others
By Geography
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the recent product approvals as one of the prime reasons driving the non-insulin diabetes therapeutics market growth during the next few years.

The report on non-insulin diabetes therapeutics market covers the following areas:
  • Non-insulin diabetes therapeutics market sizing
  • Non-insulin diabetes therapeutics market forecast
  • Non-insulin diabetes therapeutics market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-insulin diabetes therapeutics market vendors that include Abbott Laboratories, AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, and Sanofi SA. Also, the non-insulin diabetes therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Type
  • Market segments
  • Comparison by Type
  • DPP4 inhibitor - Market size and forecast 2020-2025
  • GLP-1 receptor agonist - Market size and forecast 2020-2025
  • SGLT2 inhibitor - Market size and forecast 2020-2025
  • Others - Market size and forecast 2020-2025
  • Market opportunity by Type
Customer landscape
  • Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Sanofi SA
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Type - Market share 2020-2025 (%)
  • Comparison by Type
  • DPP4 inhibitor - Market size and forecast 2020-2025 ($ million)
  • DPP4 inhibitor - Year-over-year growth 2020-2025 (%)
  • GLP-1 receptor agonist - Market size and forecast 2020-2025 ($ million)
  • GLP-1 receptor agonist - Year-over-year growth 2020-2025 (%)
  • SGLT2 inhibitor - Market size and forecast 2020-2025 ($ million)
  • SGLT2 inhibitor - Year-over-year growth 2020-2025 (%)
  • Others - Market size and forecast 2020-2025 ($ million)
  • Others - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Type
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Key customers
  • Abbott Laboratories - Segment focus
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product and service
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Key customers
  • AstraZeneca Plc - Segment focus
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Business segments
  • Eli Lilly and Co. - Key offerings
  • Eli Lilly and Co. - Key customers
  • Eli Lilly and Co. - Segment focus
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Key customers
  • Johnson and Johnson - Segment focus
  • Merck KGaA - Overview
  • Merck KGaA - Business segments
  • Merck KGaA - Key offerings
  • Merck KGaA - Key customers
  • Merck KGaA - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Novo Nordisk AS - Overview
  • Novo Nordisk AS - Business segments
  • Novo Nordisk AS - Key offerings
  • Novo Nordisk AS - Key customers
  • Novo Nordisk AS - Segment focus
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key offerings
  • Sanofi SA - Key customers
  • Sanofi SA - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • MORE
The publisher recognizes the following companies as the key players in the global non-insulin diabetes therapeutics market: Abbott Laboratories, AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, and Sanofi SA.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is recent product approvals.'

According to the report, one of the major drivers for this market is the increasing number of people with type 2 diabetes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Sanofi SA
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll